A phase II study of Paclitaxel combined with Bevacizumab in HER2 negative metastatic Breast Cancer
Phase 2
- Conditions
- metastatic Breast Cancer
- Registration Number
- JPRN-UMIN000008140
- Lead Sponsor
- Kobe Breast Cancer Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1) Previously treated with bevacizumab 2) Primary chemotherapy refractory with Paclitaxel 3) The operation has been scheduled for the examination period 4) Uncontrollable hypertension 5) Symptomatic brain metastasis 6) Anaphylaxis against drugs used in protocol treatment 7) Uncontrollable ascites, pleural effusion 8) Active infection, Severe complications (abnormal electrocardiogram, heart failure, arrhythmia, thromboembolism, etc) 9) Severe infection or serious complications, such as hypoalimentation 10) Other active malignancies 11) Pregnant or nursing women or women who like be pregnant and men with partner willing to get pregnant 12) Doctors decision for exclusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method